Advanced search

(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells

Full text
Author(s):
Petrilli, Raquel ; Eloy, Josimar O. ; Lopez, Renata F. V. ; Lee, Robert J.
Total Authors: 4
Document type: Journal article
Source: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY; v. 17, n. 2, p. 301-308, 2017.
Web of Science Citations: 0
Abstract

Background: Topical chemotherapy of skin cancers is a promising strategy for reduction of side effects and for improvement of patient compliance. The combination of the chemotherapeutic 5-fluouracil (5-FU) and the antiEGFR antibody cetuximab is a strategy to inhibit tumor growth. Their skin penetration, however, is hampered by their high hydrophilicity, which could be improved by encapsulation in delivery systems. Furthermore, it is a challenge to encapsulate hydrophilic drugs. The conjugation of an antibody to a liposome, maintaining its activity, is also a difficult task. Objective: Thus, we aimed to develop 5-FU liposomes and cetuximab-conjugated liposomes (immunoliposomes) of 5-FU to improve drug cytotoxicity against skin cancer cells. Method: We characterized them by particle size, zeta potential, loading efficiency and antibody integrity. To optimize the loading efficiency of 5-FU, a series of liposomes were prepared, using different methods and drug-to-lipid ratios. Results: Liposomes containing DSPC and Chol at drug-to-lipid ratio 0.1 prepared by the thin lipid hydration method resulted in the best 5-FU encapsulation and were chosen to conjugate with cetuximab. Cetuximab was directly coupled to preformed liposomes using DSPE-mPEG2000-Mal as an anchor. In A431 skin carcinoma cells, at 72 h, 5-FU liposomes showed a 5-fold lower IC50 than 5-FU solution. Additionally, 5-FU immunoliposomes resulted in a 4-fold lower cetuximab IC50 than cetuximab solution, demonstrating synergism with a combination index lower than 1 and potential to improve 5-FU and cetuximab cytotoxicity. Conclusion: Liposomes and immunoliposomes containing 5-FU were developed and cetuximab remained active as demonstrated in cell culture studies. (AU)

FAPESP's process: 12/23764-3 - Topical application of liposomes containing cetuximab: the effect of physical skin penetration enhancement techniques for cutaneous squamous cell carcinoma
Grantee:Raquel Petrilli
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 13/15134-2 - Preparation of immunoliposomes for topical skin cancer treatment
Grantee:Raquel Petrilli
Support type: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 14/22451-7 - Sustained drug delivery systems targeting the epithelial tissue
Grantee:Renata Fonseca Vianna Lopez
Support type: Research Projects - Thematic Grants